Cruz, CatelineMidões, CristianaNascimento, LuísArduino2025-10-242025-10-242025Cruz, Cateline; Midões, Cristiana; Nascimento, Luís (2025). The use of nanopharmaceuticals in the treatment of neoplasms - a review. In 13th APLF Annual Conference. Aveiro. ISSN 2042-0986. 16:5, p. 46-472042-09862042-0994http://hdl.handle.net/10198/34881Cancer is defined by the uncontrolled growth of cells, primarily driven by genetic mutations. Traditional treatments such as surgery, radiotherapy, and chemotherapy frequently fall short due to issues of non-specific targeting and systemic toxicity. However, nanotechnology has decisively emerged as a vital solution to these problems. Nanopharmaceuticals are rigorously formulated, nanoscale pharmaceutical products that have received regulatory approval, while nanoparticle-based therapies represent a broader range of experimental applications. Objectives: This review aims to assertively evaluate the relevance and effectiveness of nanopharmaceuticals in treating neoplasms based on solid scientific evidence. Methods: A systematic review was conducted, leveraging PubMed, MeSH Browser, SciELO, and Web of Science, focusing exclusively on articles published between January 2012 and October 2022 that pertain to nanotherapy for cancer. Studies addressing nanopharmaceuticals in non-cancer conditions or solely concentrating on conventional cancer treatments were rigorously excluded. Results: The analysis of ten selected articles demonstrates that nanoparticle-based therapies provide significant advantages over conventional treatments. These include enhanced intracellular uptake, improved biodistribution, and heightened drug accumulation at tumor sites. Notable nanopharmaceuticals such as SGT-94, BCc1, nab-paclitaxel, and others displayed superior pharmacokinetics and targeted delivery while minimizing systemic toxicity. The majority of studies reported robust safety profiles with manageable side effects and no serious toxicity. Conclusion: Nanomedicine represents a groundbreaking strategy for advancing cancer treatment by enhancing therapeutic precision and reducing adverse side effects. The compelling evidence firmly supports the expanding role of nanopharmaceuticals in oncology. It is imperative that further clinical studies validate their long-term efficacy and safety across larger populations.engNanoparticlesAntineoplasticDrug delivery systemsconference object10.1177/ 20420986251379201